Shlomo Melmed
Associate Dean, Cedars-Sinai Medical Center · UCLA David Geffen School of Medicine/UCLA Medical Center
Credentials: · ·
History
Internal Medicine
Research
Acromegaly: an endocrine society clinical practice guideline
The Journal of Clinical Endocrinology & Metabolism · 2014 · 1,272 citations
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline
Review · The Journal of Clinical Endocrinology & Metabolism · 2011 · First of 8 authors · 1,186 citations
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)
Review · The Journal of Clinical Endocrinology & Metabolism · 2012 · 977 citations
44 papers · 3 as a fellow
- MF
39 papers
- JH
22 papers
- AB
20 papers
19 papers
19 papers · 17 as a fellow
- VB
18 papers
- AK
16 papers
Grants
- 2018–2028
Mechanisms for GH Action on Epithelial Cells
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $3M · Cedars-Sinai Medical Center
- 2018–2026
Ph 2 Multicenter Study of Seliciclib for Cushing Disease IND 120,848 (10/10/2017)
Food and Drug Administration · R01
Contact PI · $2M · Cedars-Sinai Medical Center
- 1999–2025
Training Program in Endocrinology, Diabetes, and Metabolism
National Institute of Diabetes and Digestive and Kidney Diseases · T32
Contact PI · $3.6M · Cedars-Sinai Medical Center
- 2021–2022
Regulation of Age-Associated DNA Damage
National Institute on Aging · R56
Contact PI · $342.4K · Cedars-Sinai Medical Center
Clinical trials
- 2018–2026
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
Principal investigator · Recruiting · Phase 2
Cedars-Sinai Medical Center
- 2014–2018
Treatment of Cushing's Disease With R-roscovitine
Principal investigator · Terminated · Phase 2
Shlomo Melmed, MD
- 2012–2022
Acromegaly Combination Treatment Study
Principal investigator · Terminated
Cedars-Sinai Medical Center
- 2010–2013
Tissue Biomarker for Pegvisomant Action
Principal investigator · Completed
Cedars-Sinai Medical Center